Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Research & Development: 2020-2024

Historic Research & Development for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to $121.6 million.

  • Monte Rosa Therapeutics' Research & Development rose 32.81% to $36.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.4 million, marking a year-over-year increase of 26.00%. This contributed to the annual value of $121.6 million for FY2024, which is 9.25% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Research & Development of $121.6 million as of FY2024, which was up 9.25% from $111.3 million recorded in FY2023.
  • Monte Rosa Therapeutics' Research & Development's 5-year high stood at $121.6 million during FY2024, with a 5-year trough of $24.0 million in FY2020.
  • Its 3-year average for Research & Development is $106.0 million, with a median of $111.3 million in 2023.
  • Data for Monte Rosa Therapeutics' Research & Development shows a peak YoY surged of 138.10% (in 2021) over the last 5 years.
  • Monte Rosa Therapeutics' Research & Development (Yearly) stood at $24.0 million in 2020, then soared by 138.10% to $57.2 million in 2021, then spiked by 48.83% to $85.1 million in 2022, then soared by 30.81% to $111.3 million in 2023, then grew by 9.25% to $121.6 million in 2024.